Oral desvenlafaxine extended-release [Deller® (Brazil); Pristiq® (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women with vasomotor symptoms (VMS), significantly reducing the number and severity of hot flushes during 12-week trials, with these benefits maintained during longer-term therapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Lepine J-P, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):3–7.
Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease study 2010. PLoS Med. 2013;8(7):e69637.
Belmaker RH, Agam R. Major depressive disorder. N Engl J Med. 2008;358(1):55–68.
Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health. 2007;10:247–57.
Qaseem A, Barry MJ, Kansagara D, et al. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164:350–9.
Deller (desvenlafaxine succinate monohydrate): Brazilian information for health professionals [in Portuguese]. São Paulo: Aché Laboratórios Farmacêuticos S.A; 2016.
Pristiq® (desvenlafaxine) extended-release tablets, for oral use: US prescribing information: Philadelphia (PA): Pfizer Inc.; 2017.
Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–53.
Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013;19(1):5–14.
Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–90.
Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31(Pt 1):1405–23.
Clayton AH, Tourian KA, Focht K, et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015;76(5):562–9.
Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74(10):1010–7.
Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569–76.
Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71(8):1088–96.
Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17(4):700–11.
Carrasco JL, Kornstein SG, McIntyre RS, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016;31(3):134–46.
Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010;30(3):294–9.
Mosca D, Zhang M, Prieto R, et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol. 2017;37(2):182–92.
McIntyre RS, Fayyad R, Mackell JA, et al. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. Curr Med Res Opin. 2016;32(3):587–99.
Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013;74(2):158–66.
Boyer P, Vialet C, Hwang E, et al. Efficacy of desvenlafaxine 50 mg/d versus placebo in the long-term treatment of major depressive disorder: a randomized, double-blind trial. Prim Care Companion CNS Disord. 2015. doi:10.4088/PCC.14m01711.
Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200(2):172.e1–10.
Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009;200(3):238.e1–10.
Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15(1):12–20.
Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013;20(1):28–37.
Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111(1):77–87.
Pinkerton JV, Archer DF, Guico-Pabia CJ, et al. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013;20(1):38–46.
Cheng RJ, Dupont C, Archer DF, et al. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2013;16(1):17–27.
Archer DF, Pinkerton JV, Guico-Pabia CJ, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause. 2013;20(1):47–56.
Nutt DJ, Davidson JRT, Gelenberg AJ, et al. International consensus statement of major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.
North American Menospause Society. Nonhormonal management of menopause-asscoiated vasomotor symptoms: 2015 position statement of the North American Menopause Society. Menopause. 2015;22(11):1–18.
The manuscript was reviewed by: N. Cebotarenco, Coalition for Rational and Safe Use of Medicines (CoRSUM), Chişinău, Republic of Moldova; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India. During the peer review process, the marketing authorization holder of desvenlafaxine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
The preparation of this review was not supported by any external funding.
Conflict of interest
Lesley Scott is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/30FBF0605D9F6BA0.
About this article
Cite this article
Scott, L.J. Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use. Drugs Ther Perspect 33, 449–454 (2017). https://doi.org/10.1007/s40267-017-0439-1